health
April 16, 2026
What’s the deal with Alzheimer’s disease and amyloid?
For decades, scientists have concentrated on what now looks to be a blind alley.
TL;DR
- A 2011 paper claiming amyloid-beta's role in Alzheimer's-related memory loss was retracted due to falsified data.
- Multiple studies and drugs targeting amyloid-beta have failed to show significant clinical efficacy in treating Alzheimer's disease.
- The FDA's approval of aducanumab and lecanemab, both targeting amyloid-beta, was controversial due to limited evidence of benefit and significant side effects.
- Alternative theories for Alzheimer's causes include neuroinflammation, viral and bacterial infections, and the gut microbiome.
- Allegations of a 'scientific groupthink' or 'Amyloid Mafia' have suggested that research funding and focus were heavily biased towards amyloid-beta, neglecting other potential avenues of investigation.
- Scientific misconduct, including data falsification, has been uncovered in landmark Alzheimer's research, further undermining the amyloid hypothesis.
Continue reading the original article